BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-9.76%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$16.2B
AUM Growth
+$16.2B
(-14%)
Cap. Flow
+$164M
Cap. Flow
% of AUM
1.01%
Top 10 Holdings %
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$45.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$44.4M |
| 3 |
Kodiak Sciences
KOD
|
$25.1M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$22M |
| 5 |
ALLK
Allakos
ALLK
|
$17.6M |
Top Sells
| 1 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$48.2M |
| 2 |
Exact Sciences
EXAS
|
$42.9M |
| 3 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
$11.4M |
| 4 |
Adaptive Biotechnologies
ADPT
|
$10.3M |
| 5 |
NextCure
NXTC
|
$8.45M |
Sector Composition
| 1 | Healthcare | 98.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Axsome Therapeutics
AXSM
$6.05B
| $52.3M | 0.32% | 889,757 +60,000 | +7% | +$3.53M |
|
27
Insmed
INSM
$28.8B
| $48.5M | 0.3% | 3,025,384 +580,119 | +24% | +$9.3M |
|
28
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $43.3M | 0.27% | 2,799,577 | – | – |
|
29
Rhythm Pharmaceuticals
RYTM
$6.85B
| $41.2M | 0.25% | 2,708,200 | – | – |
|
30
Krystal Biotech
KRYS
$4.27B
| $40.9M | 0.25% | 946,471 -88,203 | -9% | -$3.81M |
|
31
Neurogene
NGNE
$264M
| $38.7M | 0.24% | 3,397,740 | – | – |
|
|
CCXI
32
DELISTED
ChemoCentryx, Inc.
CCXI
| $34.5M | 0.21% | 859,015 +119,999 | +16% | +$4.82M |
|
|
ALLK
33
DELISTED
Allakos
ALLK
| $32.7M | 0.2% | 735,469 +395,779 | +117% | +$17.6M |
|
|
GWPH
34
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $32.5M | 0.2% | 370,845 | – | – |
|
35
Aurinia Pharmaceuticals
AUPH
$1.58B
| $24.7M | 0.15% | 1,701,929 | – | – |
|
36
Merus
MRUS
$4.98B
| $24.7M | 0.15% | 2,037,469 | – | – |
|
37
Apellis Pharmaceuticals
APLS
$3.48B
| $24M | 0.15% | 896,551 +399,582 | +80% | +$10.7M |
|
38
Assembly Biosciences
ASMB
$190M
| $22.9M | 0.14% | 1,541,618 | – | – |
|
39
BioCryst Pharmaceuticals
BCRX
$1.74B
| $21.9M | 0.13% | 10,946,166 | – | – |
|
40
Korro Bio
KRRO
$217M
| $21M | 0.13% | 1,180,162 -51,271 | -4% | -$913K |
|
|
41
Adaptive Biotechnologies
ADPT
$2.01B
| $20.7M | 0.13% | 743,734 -371,677 | -33% | -$10.3M |
|
42
Alkermes
ALKS
$4.78B
| $17.9M | 0.11% | 1,244,744 +451,614 | +57% | +$6.51M |
|
43
uniQure
QURE
$896M
| $16.9M | 0.1% | 357,083 -160,617 | -31% | -$7.62M |
|
44
Xencor
XNCR
$580M
| $12.8M | 0.08% | 428,120 | – | – |
|
45
UroGen Pharma
URGN
$900M
| $12M | 0.07% | 672,912 -158,576 | -19% | -$2.83M |
|
46
Protagonist Therapeutics
PTGX
$3.67B
| $11.9M | 0.07% | 1,679,164 +504,882 | +43% | +$3.56M |
|
|
ADAP
47
Adaptimmune Therapeutics
ADAP
$15.6M
| $10M | 0.06% | +3,690,307 | New | +$10M |
|
|
AIMT
48
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $9.72M | 0.06% | 673,908 | – | – |
|
|
UROV
49
DELISTED
Urovant Sciences Ltd.
UROV
| $9.22M | 0.06% | 1,000,000 | – | – |
|
50
Mirum Pharmaceuticals
MIRM
$3.71B
| $8.17M | 0.05% | 583,333 +250,000 | +75% | +$3.5M |
|